Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD89/FCAR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FCAR (CD89) ECD-Fc / His-tagged Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View FCAR Products |
| Gene Delivery | FCAR (CD89) Promise-ORF / Lentivirus Full-length ORF for stable cell line generation (Flow Cytometry & ADCC/ADCP assays). |
View FCAR Products |
| Benchmark Ab | Anti-FCAR (CD89) Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View FCAR Products |
| Validator | FCAR (CD89) siRNA Set For target knockdown verification in primary myeloid cells. |
View FCAR Products |
| Related Target A | EGFR Synergistic target for CD89-directed bispecific/trispecific neutrophil-engaging therapies. |
View EGFR Products |
| Related Target B | HER2 Target for IgA-based or CD89-bispecific antibody-dependent cellular cytotoxicity (ADCC) assays. |
View HER2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving Native Glycosylation for IgA Binding | HEK293 mammalian expression system ensures correct post-translational modifications. |
| Developing Stable CD89 Effector Cell Lines | Lentivirus Premade Particles for robust, high-expression stable cell line construction. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD89/FCAR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD89/FCAR therapeutics is intensifying, with major players shifting focus from traditional IgG-based platforms to IgA-based therapeutics and neutrophil-engaging bispecifics. As first-generation therapies reach the clinic, the next wave of R&D is targeting CD89 to harness the potent cytotoxic capacity of neutrophils, which are the most abundant granulocytes in human circulation. Conversely, in autoimmune and inflammatory conditions, blocking the CD89-IgA interaction represents a promising strategy to mitigate tissue damage driven by IgA immune complexes.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| IgA-based mAbs | Academic Institutions, Biotech Startups | Solid Tumors (Breast, Colorectal) | Affinity Validation (Need high-purity CD89 ECD-Fc to measure IgA-CD89 binding kinetics) |
| Bispecific Antibodies (e.g., CD89 x Tumor Antigen) | Roche (Tusk Therapeutics), Glenmark | Oncology (HER2+, EGFR+ Tumors) | Effector Cell Activation (Need Lentivirus for CD89+ stable cell lines to run ADCC assays) |
| Antagonistic mAbs | Immunology-focused Biopharma | IgA Nephropathy, Linear IgA Dermatosis | Blocking Assays (Need sequence-verified CD89 proteins and benchmark controls) |